

Labsystems Diagnostics Oy
Tiilitie 3
FI-01720 Vantaa
Finland

Your ref.
Our ref. MED/25-131rev.2
Tel. +31 88 96 83 009
Fax +31 88 96 83 100
E-mail medical.nl@dekra.com

Arnhem, 8 October 2025

Subject: Notified Body Confirmation Letter

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, DEKRA Certification B.V., a Notified Body (NB) designated against Regulation (EU) 2017/746 (IVDR) and identified by the number 0344 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of IVDR and has signed a written agreement (dated 1 February 2023) in accordance with Section 4.3, second subparagraph of Annex VII of IVDR with the following manufacturer:

Labsystems Diagnostics Oy
Tiilitie 3
FI-01720 Vantaa
Finland

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an IVDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the Directive 98/79/EC. Table 2 identifies the devices for which an IVDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the Directive 98/79/EC.

In the case of devices covered by certificates issued under Directive 98/79/EC (IVDD) that expired after 26 May 2022 and before 09 July 2024, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under IVDR by the date of IVDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 54 of IVDR or Article 92 of the IVDR respectively, by the 09 July 2024 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 110.3c of IVDR (as amended by (EU) 2024/1860), are shown below:

- 31 December 2027 for devices covered by an IVDD certificate regardless of their risk class under the IVDR
- For devices not requiring the involvement of a notified body under the IVDD, but requiring it under the IVDR and for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with Directive 98/79/EC, the following dates apply:
 - 31 December 2027, for class D devices;
 - 31 December 2028, for class C devices;
 - 31 December 2029, for class B devices and for class A devices placed on the market in sterile condition

On behalf of the Notified Body,



Freddy Godeke
Project Manager

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under Directive 98/79/EC:

Device name or Basic UDI-DI (under IVDR application)	IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the IVDR device is a substitute device, identification of the corresponding IVDD device	IVDD/ Certificate Reference(s) of the devices under IVDR application, and the NB Identification
Neonatal Toxoplasmosis IgM FEIA (6199802)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Neonatal Toxoplasmosis IgM FEIA (6199804)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Toxoplasma gondii IgG EIA (6600100)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Toxoplasma gondii IgG Avidity EIA (6600140)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Neonatal Phenylalanine (6199895, 6199896, 6199897)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Neonatal Phenylalanine calibrators (6190940)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Neonatal Phenylalanine controls (6190930)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC (7100100)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC 3.0 (7100120)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Plus (710110)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC DBS Controls (710010003)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537

NeoMass AAAC Internal Standard, Labeled Amino Acids (710010004)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Extraction Solution (710010008)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Eluent Solution (710010009)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Plus DBS Controls (710011003)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Plus Internal Standard, Labeled Amino Acids (710011004)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Plus Extraction Solution B (710011009)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
NeoMass AAAC Plus Eluent Solution (710011010)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia Pneumoniae IgM EIA (6111320)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia Pneumoniae IgG EIA (6111300)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia Pneumoniae IgA EIA (6111310)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia Pneumoniae IgG/IgM Micro-IF test (6108380, 6108382)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia Pneumoniae IgA Micro-IF test (6108390, 6108392)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia trachomatis IgG EIA (6111101)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Chlamydia trachomatis IgA EIA (6111111)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537

Biocard C. Pneumoniae IgM (3-034-000)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
M. pneumoniae + C. pneumoniae Duplex RT-PCR (8100100, 8101100, 8100101)	Class C	N/A	Certificate #1; C-02-1172-794-22 NB # 0537
Biocard Celiac test (3-028-200, 3-028-401)	Class C	N/A	Certificate #1; C-02-1172-802-22 NB # 0537
Celiatik Test (3-028-200)	Class C	N/A	Certificate #1; C-02-1172-802-22 NB # 0537
Biocard Helicobacter Pylori IgG (3-018-200)	Class C	N/A	Certificate #1; C-02-1172-802-22 NB # 0537

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under Directive 98/79/EC:

Device name or Basic UDI-DI (under IVDR application)	IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the IVDR device is a substitute device, identification of the corresponding IVDD device	IVDD Certificate Reference(s) of the devices under IVDR application, and the NB Identification
N/A	N/A	N/A	N/A

Confirmation Letter Revision History

Date	Certification Notice (No. + Ver.)	Action
2025-06-23	N/A	Initial issue
2025-09-03	N/A	Revision
2025-10-08	2301187CN01	Revision